Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... (NASDAQ: SQNM ), a life sciences company ... new publication from the large Women & Infants multi-center ... (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) ... Prenatal Diagnosis . Along with this week,s publication, the ...
... May 16, 2012  Sigma-Aldrich announced today that it has ... will mature on May 10, 2017.  The new facility ... scheduled to mature on December 11, 2012.  The $600 ... paper program and be used for general corporate purposes. ...
... Reportlinker.com announces that a new market research ...   Global Anti-Microbial Coatings ...   This report analyzes the US ... the following End-Use Segments: Indoor Air Quality, and ...
Cached Biology Technology:Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 2Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 4Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 5Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... congenital valvular heart disease. Now, in patients with this ... the Netherlands, the University of Newcastle, UK and the ... identified mutations in a gene which plays an important ... hope that these findings will lead to faster diagnosis ...
... Jan. 10, 2011 Aware, Inc. (Nasdaq: AWRE ... telecommunications and biometrics industries, today announced that on January 5, ... Jr. and John S. Stafford, III to the Aware Board ... a Class III Director and will serve on the Board,s ...
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
Cached Biology News:Researchers link gene mutations to Ebstein's anomaly 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
...
Biology Products: